Literature DB >> 25771809

A start codon CMT1X mutation associated with transient encephalomyelitis causes complete loss of Cx32.

Irene Sargiannidou1, Gun-Ha Kim, Styliana Kyriakoudi, Baik-Lin Eun, Kleopas A Kleopa.   

Abstract

X-linked Charcot-Marie-Tooth disease (CMTX1) results from numerous mutations in the GJB1 gene encoding the gap junction protein connexin32 (Cx32) and is one of the commonest forms of inherited neuropathy. Owing to the expression of Cx32 not only in Schwann cells but also in oligodendrocytes, a subset of CMT1X patients develops central nervous system (CNS) clinical manifestations in addition to peripheral neuropathy. While most GJB1 mutations appear to cause peripheral neuropathy through loss of Cx32 function, the cellular mechanisms underlying the CNS manifestations remain controversial. A novel start codon GJB1 mutation (p.Met1Ile) has been found in a CMT1X patient presenting with recurrent episodes of transient encephalomyelitis without apparent signs of peripheral neuropathy. In order to clarify the functional consequences of this mutation, we examined the cellular expression of two different constructs cloned from genomic DNA including the mutated start codon. None of the cloned constructs resulted in detectable expression of Cx32 by immunocytochemistry or immunoblot, although mRNA was produced at normal levels. Furthermore, co-expression with the other major oligodendrocyte connexin, Cx47, had no negative effect on GJ formation by Cx47. Finally, lysosomal and proteasomal inhibition in cells expressing the start codon mutant constructs failed to recover any detection of Cx32 as a result of impaired protein degradation. Our results indicate that the Cx32 start codon mutation is equivalent to a complete loss of the protein with failure of translation, although transcription is not impaired. Thus, complete loss of Cx32 function is sufficient to produce CNS dysfunction with clinical manifestations.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25771809     DOI: 10.1007/s10048-015-0442-4

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  38 in total

1.  The effects of a dominant connexin32 mutant in myelinating Schwann cells.

Authors:  Linda Jo Bone Jeng; Rita J Balice-Gordon; Albee Messing; Kenneth H Fischbeck; Steven S Scherer
Journal:  Mol Cell Neurosci       Date:  2006-06-21       Impact factor: 4.314

2.  Central nervous system involvement in four patients with Charcot-Marie-Tooth disease with connexin 32 extracellular mutations.

Authors:  M Panas; C Karadimas; D Avramopoulos; D Vassilopoulos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-12       Impact factor: 10.154

3.  Transient, recurrent, white matter lesions in X-linked Charcot-Marie-Tooth disease with novel connexin 32 mutation.

Authors:  C Oliver Hanemann; Carsten Bergmann; Jan Senderek; Klaus Zerres; Ann-Dorte Sperfeld
Journal:  Arch Neurol       Date:  2003-04

4.  Slowing of central conduction in X-linked Charcot-Marie-Tooth neuropathy shown by brain stem auditory evoked responses.

Authors:  G Nicholson; A Corbett
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-07       Impact factor: 10.154

5.  Connexins are critical for normal myelination in the CNS.

Authors:  Daniela M Menichella; Daniel A Goodenough; Erich Sirkowski; Steven S Scherer; David L Paul
Journal:  J Neurosci       Date:  2003-07-02       Impact factor: 6.167

6.  Unique distributions of the gap junction proteins connexin29, connexin32, and connexin47 in oligodendrocytes.

Authors:  Kleopas A Kleopa; Jennifer L Orthmann; Alan Enriquez; David L Paul; Steven S Scherer
Journal:  Glia       Date:  2004-09       Impact factor: 7.452

7.  Loss-of-function GJA12/Connexin47 mutations cause Pelizaeus-Merzbacher-like disease.

Authors:  Jennifer L Orthmann-Murphy; Alan D Enriquez; Charles K Abrams; Steven S Scherer
Journal:  Mol Cell Neurosci       Date:  2007-01-25       Impact factor: 4.314

8.  Six new gap junction beta 1 gene mutations and their phenotypic expression in Czech patients with Charcot-Marie-Tooth disease.

Authors:  Dana Brozková; Radim Mazanec; Jana Haberlová; Iva Sakmaryová; Ivan Subrt; Pavel Seeman
Journal:  Genet Test Mol Biomarkers       Date:  2010-02

9.  Proteasome inhibition and oxidative reactions disrupt cellular homeostasis during heme stress.

Authors:  F Vallelian; J W Deuel; L Opitz; C A Schaer; M Puglia; M Lönn; W Engelsberger; S Schauer; E Karnaukhova; D R Spahn; R Stocker; P W Buehler; D J Schaer
Journal:  Cell Death Differ       Date:  2014-10-10       Impact factor: 15.828

10.  Inhibition of autophagy, lysosome and VCP function impairs stress granule assembly.

Authors:  S J Seguin; F F Morelli; J Vinet; D Amore; S De Biasi; A Poletti; D C Rubinsztein; S Carra
Journal:  Cell Death Differ       Date:  2014-07-18       Impact factor: 15.828

View more
  11 in total

Review 1.  Connexins and pannexins: At the junction of neuro-glial homeostasis & disease.

Authors:  Andrew S Lapato; Seema K Tiwari-Woodruff
Journal:  J Neurosci Res       Date:  2017-06-05       Impact factor: 4.164

Review 2.  Brain Disorders and Chemical Pollutants: A Gap Junction Link?

Authors:  Marc Mesnil; Norah Defamie; Christian Naus; Denis Sarrouilhe
Journal:  Biomolecules       Date:  2020-12-31

3.  Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing.

Authors:  Pongtawat Lertwilaiwittaya; Ekkapong Roothumnong; Panee Nakthong; Peerawat Dungort; Chutima Meesamarnpong; Warisara Tansa-Nga; Khontawan Pongsuktavorn; Supakit Wiboonthanasarn; Warunya Tititumjariya; Wanna Thongnoppakhun; Sirisak Chanprasert; Chanin Limwongse; Manop Pithukpakorn
Journal:  Breast Cancer Res Treat       Date:  2021-03-01       Impact factor: 4.872

4.  Systemic inflammation disrupts oligodendrocyte gap junctions and induces ER stress in a model of CNS manifestations of X-linked Charcot-Marie-Tooth disease.

Authors:  Margarita Olympiou; Irene Sargiannidou; Kyriaki Markoullis; Christos Karaiskos; Alexia Kagiava; Styliana Kyriakoudi; Charles K Abrams; Kleopas A Kleopa
Journal:  Acta Neuropathol Commun       Date:  2016-09-01       Impact factor: 7.801

5.  Loss of Coupling Distinguishes GJB1 Mutations Associated with CNS Manifestations of CMT1X from Those Without CNS Manifestations.

Authors:  Charles K Abrams; Mikhail Goman; Sarah Wong; Steven S Scherer; Kleopas A Kleopa; Alejandro Peinado; Mona M Freidin
Journal:  Sci Rep       Date:  2017-01-10       Impact factor: 4.379

6.  Clinical and Genetic Features of Chinese X-linked Charcot-Marie-Tooth Type 1 Disease.

Authors:  Yuan-Yuan Lu; He Lyu; Su-Qin Jin; Yue-Huan Zuo; Jing Liu; Zhao-Xia Wang; Wei Zhang; Yun Yuan
Journal:  Chin Med J (Engl)       Date:  2017-05-05       Impact factor: 2.628

7.  Biochemical and cellular consequences of the antithrombin p.Met1? mutation identified in a severe thrombophilic family.

Authors:  José Navarro-Fernández; María Eugenia de la Morena-Barrio; Emma Martínez-Alonso; Ingunn Dybedal; Mara Toderici; Nataliya Bohdan; Antonia Miñano; Ketil Heimdal; Ulrich Abildgaard; José Ángel Martínez-Menárguez; Javier Corral; Vicente Vicente
Journal:  Oncotarget       Date:  2018-09-04

8.  Regulatory role of oligodendrocyte gap junctions in inflammatory demyelination.

Authors:  Christos P Papaneophytou; Elena Georgiou; Christos Karaiskos; Irene Sargiannidou; Kyriaki Markoullis; Mona M Freidin; Charles K Abrams; Kleopas A Kleopa
Journal:  Glia       Date:  2018-10-16       Impact factor: 7.452

9.  The role of oligodendrocyte gap junctions in neuroinflammation.

Authors:  Christos Papaneophytou; Elena Georgiou; Kleopas A Kleopa
Journal:  Channels (Austin)       Date:  2019-12       Impact factor: 2.581

10.  The c.1A > C start codon mutation in CLN3 is associated with a protracted disease course.

Authors:  Willemijn F E Kuper; Claudia van Alfen; Linda van Eck; Stella A de Man; Marjolein H Willemsen; Koen L I van Gassen; Monique Losekoot; Peter M van Hasselt
Journal:  JIMD Rep       Date:  2020-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.